Evolving Landscape of HR+ Metastatic Breast Cancer Management
Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Other Targets in HR+ Breast Cancer: PARP Inhibition and Immune Checkpoint Inhibitors
Expert panelists consider the appropriate use of PARP and immune checkpoint inhibitors, respectively, in the setting of HR+ metastatic breast cancer.
Potential for Targeting Trop-2 in HR+ Metastatic Breast Cancer
A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.
Considering HER2-Directed Therapy in HER2-Low Metastatic Breast Cancer
Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.
Novel Treatment Modalities Under Investigation in HR+ Metastatic Breast Cancer
After briefly addressing resistance to endocrine therapy, expert panelists broadly review novel treatment modalities in the setting of HR+ metastatic breast cancer.
Patient Scenario 2: A Case of Relapsed HR+ Metastatic Breast Cancer
Expert perspectives review a case of relapsed HR+ metastatic breast cancer and consider treatment options available in the second line and beyond.
HR+ Breast Cancer: Factors in Selecting First-Line Therapy for Metastatic Disease
Highlights from key clinical data informing the selection of targeted therapy in particular subsets of patients with HR+ breast cancer.
Role of CDK4/6 Inhibitors as First-Line Therapy for Metastatic HR+ Breast Cancer
Comprehensive insight to the selection of CDK4/6 inhibitors as first-line therapy for patients with metastatic HR+ breast cancer, followed by a brief review of available endocrine partners.
Patient Scenario 1: A Case of Stage II HR+ Breast Cancer
Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.
